PharmaEngine (4162) — Cash Flow Quality Index
PharmaEngine (4162) has a Cash Flow Quality Index of 0.39x as of September 2025. Operating cash flow of NT$53.01 Million is below net income of NT$136.46 Million, suggesting accrual-heavy earnings not yet converted to cash. Also explore PharmaEngine asset portfolio for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
PharmaEngine Cash Flow Quality Index (2011–2024)
Historical Cash Flow Quality Index for PharmaEngine across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check PharmaEngine tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for PharmaEngine (2011–2024)
Year-by-year earnings quality comparison for PharmaEngine. For live market cap and the full company financial profile, see how much is PharmaEngine worth.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.26x | NT$456.73 Million | NT$1.75 Billion | ▼ -72.1% |
| 2023 | 0.94x | NT$256.97 Million | NT$274.65 Million | ▲ +81.8% |
| 2022 | 0.51x | NT$202.01 Million | NT$392.46 Million | ▼ -69.8% |
| 2021 | 1.70x | NT$929.67 Million | NT$545.39 Million | ▲ +1880.4% |
| 2020 | 0.09x | NT$64.77 Million | NT$752.48 Million | ▼ -73.4% |
| 2019 | 0.32x | NT$16.08 Million | NT$49.67 Million | ▼ -92.9% |
| 2018 | 4.55x | NT$745.23 Million | NT$163.77 Million | ▲ +766.5% |
| 2017 | -0.68x | NT$-339.30 Million | NT$496.99 Million | ▼ -165.7% |
| 2016 | 1.04x | NT$870.38 Million | NT$837.91 Million | ▼ -5.6% |
| 2015 | 1.10x | NT$447.99 Million | NT$406.99 Million | ▲ +4.4% |
| 2014 | 1.05x | NT$131.09 Million | NT$124.32 Million | ▼ -24.8% |
| 2012 | 1.40x | NT$68.64 Million | NT$48.99 Million | ▲ +45.3% |
| 2011 | 0.96x | NT$275.49 Million | NT$285.71 Million | — |